Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis

• ClinicalTrials.gov Identifier: NCT02763111
• Recruitment Status: Completed
• First Posted: May 5, 2016
• Last Update Posted: November 1, 2021
• Sponsor: Biocad
• Information provided by (Responsible Party): Biocad

Study Description

Brief Summary:

BCD-085-3 is a next step in clinical investigation of BCD-085. BCD-085 is a monoclonal antibody to interleukin 17. During the trial patients with active ankylosing spondylitis will receive 40, 80 or 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12. Efficacy and safety parameters will be evaluated.

Condition or disease	Intervention/treatment	Phase
Ankylosing Spondylitis	Drug: BCD-085; Other: Placebo	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 88 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: International Multi-center Comparative Randomized Double-blind Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Active Ankylosing Spondylitis
• Study Start Date: September 2016
• Actual Primary Completion Date: June 2017
• Actual Study Completion Date: June 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: BCD-085, 40 mg; Patient will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.	Drug: BCD-085
Experimental: BCD-085, 80 mg; Patient will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.	Drug: BCD-085
Experimental: BCD-085, 120 mg; Patient will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.	Drug: BCD-085
Placebo Comparator: Placebo; Patient will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.	Other: Placebo

Outcome Measures

Primary Outcome Measures :

1. Ratio of patients with ASAS20 response after 16 weeks of therapy [ Time Frame: Week 16 ]
   Ratio of patients who developed a decrease in ankylosing spondylitis assessment score (ASAS) by 20% or more after 16 weeks of therapy with BCD-085.

Secondary Outcome Measures :

1. Ratio of patients with ASAS20 response after 4, 8, 12 weeks of therapy [ Time Frame: Week 4, Week 8, Week 12 ]
   Ratio of patients who developed a decrease in ankylosing spondylitis assessment score (ASAS) by 20% or more after 4, 8, 12 weeks of therapy with BCD-085.
2. Ratio of patients with ASAS40 response after 4, 8, 12, 16 weeks of therapy [ Time Frame: Week 4, Week 8, Week 12, Week 16 ]
   Ratio of patients who developed a decrease in ankylosing spondylitis assessment score (ASAS) by 40% or more after 4, 8, 12, 16 weeks of therapy with BCD-085.
3. Ratio of patients with ASAS5/6 response after 4, 8, 12, 16 weeks of therapy [ Time Frame: Week 4, Week 8, Week 12, Week 16 ]
   Ratio of patients who developed a response in at least 5 of 6 criteria of ankylosing spondylitis assessment score (ASAS) after 4, 8, 12, 16 weeks of therapy with BCD-085.
4. Mean BASDAI score at screening and after 4, 8, 12, 16 weeks of therapy [ Time Frame: Screening, Week 4, Week 8, Week 12, Week 16 ]
   Mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score at screening and after 4, 8, 12, 16 weeks of therapy
5. Mean BASMI score at screening and after 4, 8, 12, 16 weeks of therapy [ Time Frame: Screening, Week 4, Week 8, Week 12, Week 16 ]
   Mean Bath Ankylosing Spondylitis Metrology Index (BASMI) score at screening and after 4, 8, 12, 16 weeks of therapy
6. Mean MASES score at screening and after 4, 8, 12, 16 weeks of therapy [ Time Frame: Screening, Week 4, Week 8, Week 12, Week 16 ]
   Mean Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at screening and after 4, 8, 12, 16 weeks of therapy
7. Mean chest excursion at screening and after 4, 8, 12, 16 weeks of therapy [ Time Frame: Screening, Week 4, Week 8, Week 12, Week 16 ]
   Mean chest excursion at screening and after 4, 8, 12, 16 weeks of therapy measured by Cloth Tape Measure Technique
8. Mean BASFI score at screening and after 4, 8, 12, 16 weeks of therapy [ Time Frame: Screening, Week 4, Week 8, Week 12, Week 16 ]
   Mean Bath Ankylosing Spondylitis Functional Index (BASFI) score at screening and after 4, 8, 12, 16 weeks of therapy
9. Mean ASDAS-CRP score at screening and after 4, 8, 12, 16 weeks of therapy [ Time Frame: Screening, Week 4, Week 8, Week 12, Week 16 ]
   Mean Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) score at screening and after 4, 8, 12, 16 weeks of therapy
10. Mean SF-36 score at screening and after 8 and 16 weeks of therapy [ Time Frame: Screening, Week 8, Week 16 ]
    Mean Short Form-36 (SF36) score at screening and after 8, 16 weeks of therapy
11. Mean pain score during a day at screening and after 1, 2, 4, 8, 12, 16 weeks of therapy [ Time Frame: Screening, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16 ]
    Mean pain score during a day at screening and after 1, 2, 4, 8, 12, 16 weeks of therapy measured by Visual Analog Scale for Pain
12. Proportion of patients with deterioration of roentgenologic signs of sacroileitis after 16 weeks of treatment [ Time Frame: Week 16 ]
13. Mean C-reactive protein concentration at screening and after 4, 8, 12 and 16 weeks of treatment. [ Time Frame: Screening, Week 4, Week 8, Week 12, Week 16 ]
14. Frequency of AE/SAE [ Time Frame: 16 weeks ]
15. Frequency of local reactions [ Time Frame: 16 weeks ]
16. Frequency of AE/SAE 3-4 grade CTCAE 4.03 [ Time Frame: 16 weeks ]
17. Frequency of withdrawals due to AE/SAE [ Time Frame: 16 weeks ]
18. Cmin [ Time Frame: 0 to 168 hours post-dose ]
    Minimal concentration of BCD-085 in blood after drug injection
19. AUC (0-168h) [ Time Frame: 0 to 168 hours post-dose ]
    Area under curve from 0 to 168 hours of BCD-085 in blood after drug injection
20. AUC0-∞ [ Time Frame: 0 to 168 hours post-dose ]
    Area under curve from 0 to infinity of BCD-085 in blood after drug injection
21. Cmax [ Time Frame: 0 to 168 hours post-dose ]
    Maximal concentration of BCD-085 in blood after drug injection
22. Тmax [ Time Frame: 0 to 168 hours post-dose ]
    Time before Cmax of BCD-085 is reached in blood after drug injection
23. Т½ [ Time Frame: 0 to 168 hours post-dose ]
    Half-life of BCD-085 in blood after drug injection
24. Кel [ Time Frame: 0 to 168 hours post-dose ]
    Elimination rate constant of BCD-085 in blood after drug injection
25. Cl [ Time Frame: 0 to 168 hours post-dose ]
    Clearance of BCD-085 in blood after drug injection
26. Proportion of patients who developed binding and neutralizing antibodies to BCD-085 [ Time Frame: 16 weeks ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Written informed consent
• Age between 18 and 65 years
• Active ankylosing spondylitis according to modified criteria of New York classification (1984), that was diagnosed at least 3 months prior to screening.
• Active disease according to BASDAI (score 4 or more) if nonsteroidal antiinflammatory drugs were used in the last 3 month prior to screening.
• Mean backache intensity equals 4 points or more.
• If patient have had biologic therapy to treat ankylosing spondylitis for at least 3 months, there was no positive results of such treatment or patient revealed intolerance to the drug. This therapy must be discontinued at least 12 weeks before enrollment in the study.
• Female patients have negative urine pregnancy test.
• Patient has no history of tuberculosis.
• Patients have negative results of Diaskintest.
• Patient has no history of alcohol or drug abuse.

Exclusion Criteria:

• Total spinal ankylosis.
• Allergy or intolerance of monoclonal antibodies or any excipients of study drugs.
• Previous receipt of anti-interleukin 17 drugs or anti-interleukin 17 receptor drugs.
• Prior use of two or more biologics to tumor necrosis factor alfa.
• Prior use of two or more biologics to other targets. Previous receipt of monoclonal antibodies if they were cancelled less that in 12 weeks before signing informed consent.
• Patient is taking corticosteroids for up to 4 weeks in a dose more than 10 mg (recalculated to prednisolone) before signing informed consent and during screening, or in a dose less than 10 mg (recalculated to prednisolone) if it was not stable.
• Prior use of disease-modifying antirheumatic drugs including methotrexate, sulfasalazin, chloroquine or hydroxychloroquine for up to 4 weeks before randomization, if their dose was not stable for up to 4 weeks before signing informed consent and during screening.
• Prior use of live or attenuated vaccines for up to 8 weeks before signing informed consent.
• Prior use of alkylating agents for up to 12 months prior to signing informed consent.
• Intraarticular use of corticosteroids for up to 4 weeks before randomization.

Contacts and Locations

Sponsors and Collaborators

Biocad

Investigators

• Study Chair: Roman Ivanov, PhD; JCS BIOCAD

More Information

Publications of Results:

Erdes S, Nasonov E, Kunder E, Pristrom A, Soroka N, Shesternya P, Dubinina T, Smakotina S, Raskina T, Krechikova D, Povarova T, Plaksina T, Gordeev I, Mazurov V, Reshetko O, Zonova E, Eremeeva A, Chernyaeva E, Makulova T, Ivanov R. Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. Clin Exp Rheumatol. 2020 Jan-Feb;38(1):27-34. Epub 2019 Apr 16.

• Responsible Party: Biocad
• ClinicalTrials.gov Identifier: NCT02763111
• Other Study ID Numbers: BCD-085-3
• First Posted: May 5, 2016
• Last Update Posted: November 1, 2021
• Last Verified: October 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Biocad:

ankylosing spondylitis; interleukin 17; monoclonal antibody

Additional relevant MeSH terms:

Spondylitis; Spondylitis, Ankylosing; Bone Diseases, Infectious; Infections; Bone Diseases; Musculoskeletal Diseases; Spinal Diseases; Spondylarthropathies; Spondylarthritis; Ankylosis; Joint Diseases; Arthritis